default author photo

Javier Ros

affiliation not provided to SSRN

  • affiliation not provided to SSRN

SCHOLARLY PAPERS

2

DOWNLOADS

141

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Association between sex and response to encorafenib-based combinations in BRAF V600E mutant metastatic colorectal cancer

Downloads 92 (730,864)

Association between sex and response to encorafenib-based combinations in BRAF V600E mutant metastatic colorectal cancer

Number of pages: 30 Posted: 31 Aug 2025
Javier Ros, Víctor Navarro, Guillermo Villacampa, Raquel Comas Navarro, Alessandra Boccaccino, Iosune Baraibar, Vincenzo Nasca, Nadia Saoudi Gonzalez, Francesc Salvà, Marta Rodriguez, Adriana Alcaraz, Ariadna Garcia Rodriguez, Javier Carmona and Marco Maria Germani
affiliation not provided to SSRN, Vall d'Hebron Institute of Oncology (VHIO), affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pisa - Department of Translational Research and of New Surgical and Medical Technologies, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and Ospedale Santa Chiara - Azienda Ospedaliero Universitaria Pisana
Downloads 65 (929,821)

Abstract:

Loading...

BRAF mutation, Colorectal cancer, Biomarker, Sex, MEK inhibitor, binimetinib

Association between sex and response to encorafenib-based combinations in BRAF V600E mutant metastatic colorectal cancer

Number of pages: 52 Posted: 24 Nov 2025
Javier Ros, Víctor Navarro, Guillermo Villacampa, Raquel Comas Navarro, Alessandra Boccaccino, Iosune Baraibar, Vincenzo Nasca, Nadia Saoudi Gonzalez, Francesc Salvà, Marta Rodriguez, Adriana Alcaraz, Ariadna Garcia Rodriguez, Javier Carmona, Marco Maria Germani, Francesca Bergamo, Lisa Salvatore, Beatrice Borelli, Alessandro Passardi, Lorenzo Antonuzzo, Guglielmo Vetere, Stefano Tamberi, Sara Lonardi, Filippo Pietrantonio, Chiara Cremolini, Josep Tabernero, Josep Tabernero and Maria Elena Elez
affiliation not provided to SSRN, Vall d'Hebron Institute of Oncology (VHIO), affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pisa - Department of Translational Research and of New Surgical and Medical Technologies, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Ospedale Santa Chiara - Azienda Ospedaliero Universitaria Pisana, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Medical Oncology 1, Fondazione Policlinico Universitario A. Gemelli IRCCS - Oncologia Medica, University Hospital of Pisa - Unit of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) - Department of Medical Oncology, Careggi University Hospital of Florence - Clinical Oncology Unit, Ospedale Santa Chiara - Azienda Ospedaliero Universitaria Pisana, AUSL Romagna - Oncology Unit, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, University Hospital of Pisa - Unit of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO)Hospital Vall d’Hebron and Vall d’Hebron Institute of Oncology (VHIO)
Downloads 27 (1,400,723)

Abstract:

Loading...

BRAF mutation, colorectal cancer, Biomarker, sex, MEK inhibitor, binimetinib

2.

Prognostic Impact of the Braf V600e Mutation in Patients with Msi-High Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors

Number of pages: 29 Posted: 29 Apr 2025
Claire Gallois, Margherita Ambrosini, Sara Lonardi, Emily Alouani, Rosine Guimbaud, Michael J. Overman, Frank Sinicrope, Thibaut Mazard, Marie Decraecker, Javier Ros, Maria Elena Elez, Simon Pernot, Chiara Cremolini, Alice Boilève, Pauline Parent, Priya Jayachandran, Marie Dutherage, Mathilde Mercier, Clémence Flecchia, Marwan Fakih Fakih, Francesco Sclafani, Filippo Pietrantonio, Julien Taieb and David Tougeron
affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), University of Toulouse - Hospital Rangueil, University of Toulouse - Hospital Rangueil, University of Texas at Houston - MD Anderson Cancer Center, Mayo Clinic, Université de Montpellier - Institut de Recherche en Cancérologie de Montpellier, University of Bordeaux - Hôpital Haut-Lévêque, affiliation not provided to SSRN, Vall d’Hebron Institute of Oncology (VHIO), University of Bordeaux - Institut Bergonié, University Hospital of Pisa - Unit of Medical Oncology, Gustave Roussy, University of Lille - CHU Lille, affiliation not provided to SSRN, CHU Rouen, CHU Poitiers, affiliation not provided to SSRN, City of Hope, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Université Paris Cité and Université de Poitiers - Gastroenterology Department
Downloads 49 (1,074,648)

Abstract:

Loading...

Colorectal cancer, BRAF mutation, microsatellite instability, immune checkpoint inhibitor